
Jyong Biotech Ltd. Successfully Raises $20 Million From Nasdaq IPO to Enter $11.9 Billion Urology Health Market
Taipei-based biotech company Jyong Biotech Ltd. has leveraged a successful IPO to accelerate the development of MCS-2, a promising treatment for benign prostatic hyperplasia (BPH).